Recombinant Marmoset OX40 / TNFRSF4 / CD134 Protein, His Tag, 100 µg

Background
Tumor necrosis factor receptor superfamily member 4 (TNFRSF4) is also known as ACT35 antigen, OX40L receptor, TAX transcriptionally-activated glycoprotein 1 receptor, CD antigen CD134, OX40. OX40 / TNFRSF4 contains four TNFR-Cys repeats. TNFRSF4 is receptor for TNFSF4 / OX40L / GP34 and can interacts with TRAF2, TRAF3 and TRAF5.

Source
Recombinant Marmoset OX40, His Tag (OX0-M522b) is expressed from human 293 cells (HEK293). It contains AA Leu 29 - Ala 214 (Accession # F7DHA3-1).
Predicted N-terminus: Leu 29

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 21.8 kDa. The protein migrates as 42-45 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.
 
Purity
>90% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.
 
Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Amygdalin Improves Allergic Asthma via the Thymic Stromal Lymphopoietin-dendritic Cell-OX40 Ligand Axis in a Mouse Model"
Cui, Zhou, Liu et al
Iran J Allergy Asthma Immunol (2023) 22 (5), 430-439
(2) "In vivo production of CAR-T cells using virus-mimetic fusogenic nanovesicles"
Zhao, Zhang, Xu et al
Sci Bull (Beijing) (2023)
(3) "Immune checkpoints are predominantly co-expressed by clonally expanded CD4+FoxP3+ intratumoral T-cells in primary human cancers"
Bredel, Tihic, Mouraud et al
J Exp Clin Cancer Res (2023) 42 (1), 333
Showing 1-3 of 2085 papers.